Neurotrophic Keratopathy Treated with Topical Recombinant Human Nerve Growth Factor (Cenegermin): Case Series Study with Long-Term Follow-Up.

Abstract

The authors report the use of topical recombinant human nerve growth factor cenegermin 0.02% in 5 patients diagnosed with neurotrophic keratopathy (NK) in a real-life setting. These 5 patients affected with stage II and III NK mainly of herpetic cause received cenegermin six times daily for 8 weeks. It was initiated upon refractoriness to prior conventional topical treatment. Visual acuity, corneal sensitivity test at four corneal quadrants, fluorescein staining, OC,T and photography were performed weekly during 9 weeks of follow-up from the completion of treatment. At the ninth week of follow-up, corneal sensitivity improvement and healing of corneal ulcers were found in all patients. No adverse events were reported, and no corneal ulcer recurrence was observed over a 4-year follow-up period. Cenegermin should be used in combination with conventional therapy for advanced NK, as it is an effective treatment for healing corneal ulcers, improving the corneal surface homeostasis and avoiding surgery.

• Authors: Salvador García-Delpech, Patricia Udaondo, Alex Samir Fernández-Santodomingo, Damian García-Teillard
• Journal: Case reports in ophthalmology (Case Rep Ophthalmol) 2022 May-Aug Vol. 13 Issue 2 Pg. 663-670 ISSN: 1663-2699 [Print] Switzerland
• PMID: 36160492 (Publication Type: Case Reports)
• Copyright: Copyright © 2022 by The Author(s). Published by S. Karger AG, Basel.